Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up to $4.07

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $4.07, but opened at $4.50. Autolus Therapeutics shares last traded at $4.61, with a volume of 782,622 shares changing hands.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Needham & Company LLC reissued a "buy" rating and issued a $9.00 price target on shares of Autolus Therapeutics in a research note on Friday. Truist Financial raised their target price on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the stock a "buy" rating in a research note on Tuesday, April 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $8.70.

Autolus Therapeutics Trading Up 7.9 %

The firm has a fifty day moving average price of $5.01 and a 200 day moving average price of $5.32. The firm has a market cap of $1.17 billion, a PE ratio of -3.69 and a beta of 2.03.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its earnings results on Thursday, March 14th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.18). As a group, equities analysts predict that Autolus Therapeutics plc will post -0.71 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Bayesian Capital Management LP purchased a new position in shares of Autolus Therapeutics during the 1st quarter worth approximately $100,000. China Universal Asset Management Co. Ltd. acquired a new position in Autolus Therapeutics during the fourth quarter worth $105,000. B. Riley Wealth Advisors Inc. purchased a new position in shares of Autolus Therapeutics during the first quarter worth $108,000. SG Americas Securities LLC acquired a new stake in shares of Autolus Therapeutics in the first quarter valued at $127,000. Finally, EntryPoint Capital LLC raised its holdings in shares of Autolus Therapeutics by 113.6% in the 1st quarter. EntryPoint Capital LLC now owns 21,540 shares of the company's stock valued at $137,000 after buying an additional 11,456 shares during the period. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.